

Table 19.29
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	169,687	68.1 (67.8 , 68.4)	89.0 (88.3 , 89.7)	75.8 (75.4 , 76.1)	57.4 (56.9 , 57.9)			
1 Hodgkin Lymphoma	14,949	85.3 (84.6 , 86.0)	96.4 (95.3 , 97.3)	89.4 (88.7 , 90.1)	52.8 (49.9 , 55.6)			
2 Non-Hodgkin lymphoma	150,164	66.9 (66.6 , 67.3)	87.0 (86.1 , 87.8)	74.0 (73.5 , 74.4)	58.1 (57.6 , 58.7)			
2(a) Non-Hodgkin lymphoma, B-cell	137,405	67.4 (67.0 , 67.7)	88.0 (87.0 , 88.9)	74.9 (74.5 , 75.3)	58.8 (58.2 , 59.3)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	7,176	67.6 (66.3 , 68.8)	88.0 (86.8 , 89.0)	35.4 (33.0 , 37.8)	14.0 (10.5 , 17.9)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	124,162	67.3 (67.0 , 67.7)	88.2 (86.0 , 90.1)	76.3 (75.9 , 76.7)	59.0 (58.4 , 59.5)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	29,600	76.4 (75.6 , 77.1)	- (- , -)	85.3 (84.4 , 86.2)	70.4 (69.2 , 71.5)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	26,077	79.2 (78.4 , 80.0)	- (- , -)	88.1 (87.2 , 89.0)	73.4 (72.2 , 74.6)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	114	41.6 (29.9 , 52.9)	- (- , -)	51.2 (30.8 , 68.3)	36.1 (21.9 , 50.5)			
2(a) 2.1.3. Mantle-cell lymphoma	3,409	55.6 (53.2 , 57.8)	- (- , -)	67.5 (64.4 , 70.5)	46.0 (42.6 , 49.2)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	2,699	78.2 (75.5 , 80.7)	- (- , -)	85.1 (81.7 , 87.8)	74.1 (70.2 , 77.6)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	1,207	74.0 (69.7 , 77.8)	- (- , -)	80.7 (75.0 , 85.3)	70.1 (64.0 , 75.3)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	1,492	81.5 (77.9 , 84.6)	- (- , -)	88.3 (84.0 , 91.5)	77.3 (71.9 , 81.7)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	32,750	60.5 (59.8 , 61.1)	86.4 (82.6 , 89.4)	69.9 (69.0 , 70.7)	50.7 (49.6 , 51.8)			
2(a) 2.3.1. DLBCL, NOS ^c	32,385	60.3 (59.6 , 61.0)	87.3 (83.5 , 90.2)	69.8 (68.9 , 70.6)	50.7 (49.6 , 51.8)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	36	54.8 (34.6 , 71.2)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.3. Primary effusion lymphoma	54	22.5 (10.8 , 36.8)	- (- , -)	24.8 (11.6 , 40.5)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	275	81.8 (75.3 , 86.8)	- (- , -)	86.4 (80.2 , 90.7)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	2,200	58.3 (56.0 , 60.6)	88.6 (85.2 , 91.3)	55.8 (52.8 , 58.6)	31.0 (25.1 , 37.1)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	8,856	90.0 (88.8 , 91.2)	98.2 (87.7 , 99.7)	92.9 (91.6 , 93.9)	87.4 (85.1 , 89.3)			
2(a) 2.5.1. Splenic MZL	756	84.8 (80.1 , 88.4)	- (- , -)	87.7 (82.3 , 91.5)	81.8 (74.3 , 87.3)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	5,326	94.0 (92.4 , 95.3)	97.4 (82.7 , 99.6)	95.7 (94.2 , 96.8)	92.2 (89.0 , 94.5)			
2(a) 2.5.3. Nodal MZL	2,774	83.5 (81.1 , 85.6)	- (- , -)	87.8 (84.9 , 90.1)	79.9 (76.1 , 83.1)			
2(a) 2.6. Follicular lymphoma	18,039	86.1 (85.3 , 86.9)	91.8 (75.9 , 97.4)	90.6 (89.8 , 91.4)	79.9 (78.3 , 81.5)			
2(a) 2.7. Hairy-cell leukemia	1,470	93.6 (90.8 , 95.5)	- (- , -)	97.6 (95.8 , 98.7)	82.5 (74.7 , 88.1)			
2(a) 2.8. Plasma cell neoplasms	28,523	44.6 (43.8 , 45.4)	- (- , -)	57.4 (56.3 , 58.6)	34.8 (33.7 , 35.8)			
2(a) 2.8.1. Plasmacytoma	1,778	65.0 (61.8 , 67.9)	- (- , -)	77.4 (73.8 , 80.5)	48.7 (43.5 , 53.7)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	26,745	43.3 (42.4 , 44.1)	- (- , -)	55.7 (54.5 , 56.9)	34.0 (32.9 , 35.1)			
2(a) 2.9. Heavy chain disease	25	66.6 (34.1 , 85.7)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	6,067	67.5 (65.7 , 69.2)	83.3 (65.2 , 92.5)	75.4 (73.2 , 77.5)	62.1 (59.4 , 64.6)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.29 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
2(b) Non-Hodgkin lymphoma, T-cell	10,320	63.1 (61.9 , 64.2)	83.3 (81.0 , 85.5)	66.3 (64.9 , 67.7)	49.6 (47.1 , 52.0)			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	884	62.4 (58.7 , 65.8)	84.5 (80.5 , 87.8)	44.8 (39.3 , 50.2)	8.0 (2.1 , 19.0)			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	9,351	63.4 (62.2 , 64.6)	82.7 (79.6 , 85.4)	68.1 (66.6 , 69.5)	50.7 (48.2 , 53.2)			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	2,319	89.4 (87.1 , 91.4)	94.9 (77.3 , 98.9)	93.0 (90.9 , 94.7)	80.7 (74.3 , 85.6)			
2(b) 2.1.1. Mycosis fungoides	2,254	90.6 (88.3 , 92.5)	94.9 (77.3 , 98.9)	93.6 (91.5 , 95.2)	83.0 (76.4 , 87.9)			
2(b) 2.1.2. Sezary syndrome	65	44.1 (26.8 , 60.2)	- (- , -)	57.1 (30.1 , 77.0)	33.3 (12.4 , 56.0)			
2(b) 2.2. Peripheral T-cell lymphoma	5,466	56.0 (54.4 , 57.6)	81.6 (76.2 , 85.9)	62.4 (60.4 , 64.4)	43.2 (40.3 , 46.1)			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	1,836	37.0 (34.3 , 39.7)	60.4 (44.1 , 73.4)	42.5 (38.8 , 46.1)	29.1 (25.0 , 33.4)			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	700	43.4 (38.7 , 47.9)	- (- , -)	52.6 (46.1 , 58.7)	35.2 (28.8 , 41.7)			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	76	61.6 (44.0 , 75.2)	- (- , -)	64.0 (41.2 , 79.9)	- (- , -)			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	1,189	58.1 (54.9 , 61.2)	85.2 (78.7 , 89.9)	62.0 (58.1 , 65.7)	32.0 (25.5 , 38.8)			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	43	26.8 (13.9 , 41.5)	- (- , -)	26.8 (12.0 , 44.2)	- (- , -)			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	65	13.3 (5.4 , 25.0)	- (- , -)	16.5 (5.3 , 33.1)	11.9 (3.0 , 27.5)			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	1,055	81.1 (77.2 , 84.4)	- (- , -)	85.8 (81.7 , 89.1)	73.0 (65.0 , 79.4)			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	502	90.9 (86.3 , 94.0)	- (- , -)	94.5 (89.1 , 97.2)	81.3 (69.2 , 89.0)			
2(b) 2.3. Adult T-cell leukemia/lymphoma	866	57.0 (53.2 , 60.7)	82.7 (78.3 , 86.3)	36.7 (30.5 , 42.8)	19.8 (11.4 , 29.8)			
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	412	41.6 (35.9 , 47.2)	- (- , -)	39.8 (33.3 , 46.2)	43.5 (31.1 , 55.2)			
2(b) 2.5. T-cell large granular lymphocytic leukemia	140	64.4 (52.3 , 74.2)	- (- , -)	75.8 (59.1 , 86.4)	54.7 (37.7 , 68.9)			
2(b) 2.6. Prolymphocytic leukemia, T-cell	148	21.5 (13.4 , 30.9)	- (- , -)	29.8 (18.7 , 41.7)	14.8 (5.8 , 27.8)			
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	85	36.5 (25.1 , 48.1)	- (- , -)	52.5 (35.9 , 66.7)	12.2 (2.7 , 29.4)			
2(c) Non-Hodgkin lymphoma, unknown lineage	2,439	59.0 (56.6 , 61.3)	85.5 (82.4 , 88.0)	56.1 (52.2 , 59.8)	42.0 (37.7 , 46.1)			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	1,075	64.7 (61.6 , 67.6)	85.8 (82.7 , 88.4)	37.7 (31.3 , 44.1)	19.3 (12.4 , 27.4)			
2(c) 2. Prolymphocytic leukemia, unknown lineage	57	48.5 (33.5 , 62.0)	- (- , -)	- (- , -)	38.8 (20.6 , 56.7)			
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	1,307	54.2 (50.7 , 57.6)	- (- , -)	64.9 (60.0 , 69.3)	46.4 (41.5 , 51.2)			
2(*) 1. Total precursor lymphoma/leukemia ^d	9,135	66.8 (65.7 , 67.9)	87.5 (86.4 , 88.4)	37.1 (35.0 , 39.2)	14.6 (11.6 , 18.0)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	83	60.1 (45.8 , 71.7)	- (- , -)	63.5 (46.1 , 76.6)	53.4 (29.0 , 72.7)			
4 Lymphoid neoplasm, NOS ^c	4,491	48.8 (46.9 , 50.7)	84.5 (72.3 , 91.6)	61.4 (58.6 , 64.0)	39.8 (37.2 , 42.4)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.